These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Ischemic coronary syndromes and SVG Interventions--do 2b/3a inhibitors miss the target? Topaz O Catheter Cardiovasc Interv; 2007 Apr; 69(5):630-1. PubMed ID: 17377986 [No Abstract] [Full Text] [Related]
4. Platelet glycoprotein IIb/IIIa antagonists in percutaneous coronary interventions. Gambhir DS; Mukhopadhyay S Indian Heart J; 2000; 52(5):524-32. PubMed ID: 11256774 [No Abstract] [Full Text] [Related]
5. Effects of clopidogrel pretreatment before percutaneous coronary intervention in patients treated with glycoprotein IIb/IIIa inhibitors (abciximab or tirofiban). Assali AR; Salloum J; Sdringola S; Moustapha A; Ghani M; Hale S; Schroth G; Fujise K; Anderson HV; Smalling RW; Rosales OR Am J Cardiol; 2001 Oct; 88(8):884-6, A6. PubMed ID: 11676953 [No Abstract] [Full Text] [Related]
6. Angiographic predictors of adverse outcomes in the modern interventional era. White CJ J Am Coll Cardiol; 2003 Sep; 42(6):989-90. PubMed ID: 13678917 [No Abstract] [Full Text] [Related]
7. Platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary revascularization: what more needs to be proven? Lincoff AM; Topol EJ Eur Heart J; 2000 Jun; 21(11):863-7. PubMed ID: 10806004 [No Abstract] [Full Text] [Related]
8. Will blocking the platelet save the diabetic? King SB; Mahmud E Circulation; 1999 Dec 21-28; 100(25):2466-8. PubMed ID: 10604881 [No Abstract] [Full Text] [Related]
9. Introduction: glycoprotein IIb/IIIa blockers in the era of metallic coronaries. Goldschmidt-Clermont PJ J Invasive Cardiol; 2002 Dec; 14 Suppl E():1E. PubMed ID: 12668856 [No Abstract] [Full Text] [Related]